Peripheral Blood Immunotype Classification for ICB Therapy Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using immune checkpoint blockers (ICBs) face challenges in identifying patients who are unlikely to benefit, due to the lack of validated biomarkers for patient selection and treatment guidance, particularly for those resistant to PD-1/L1 or CTLA-4 blockade therapies.
Innovation Solution
A method is developed to classify cancer patients into immunotypes (LAG+, LAG−, or PRO) based on the frequencies of specific CD8+ T-cell populations in peripheral blood using flow cytometry and a multinomial logistic regression algorithm, allowing for personalized treatment decisions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune checkpoint blockers are used to treat cancer patients, then anti-tumor response is enabled in some patients, but the ability to identify patients unlikely to benefit is limited due to lack of validated biomarkers
Solution Approach 1:
The patent segments the patient population into three distinct immunotypes (LAG+, LAG−, and PRO) based on the expression patterns of four immune markers in peripheral blood. This segmentation allows for more precise patient stratification and prediction of response to immune checkpoint blockade therapy, moving beyond binary responder/non-responder classification.
Solution Approach 2:
The patent transitions from tumor-based biomarker assessment (single dimension) to peripheral blood-based immune marker profiling (additional dimension). By measuring marker expression in easily accessible blood samples rather than requiring tumor tissue analysis, the patent adds a new dimension for biomarker assessment that improves patient selection capability.
2Productivity
If PD-1/L1 or CTLA-4 blockade is used for treatment, then immune system activation is achieved, but response rates are limited and toxicity increases without accurate patient selection
Solution Approach 1:
The patent performs preliminary classification of patients into immunotypes using peripheral blood markers before initiating immune checkpoint blockade therapy. This preliminary assessment identifies patients most likely to benefit from treatment, allowing clinicians to select appropriate patients in advance and avoid exposing non-responders to unnecessary therapy-related toxicities.
Solution Approach 2:
The patent changes the parameters used for patient selection from traditional tumor-based markers (PD-L1 expression, tumor mutation burden) to peripheral blood-based immune marker profiles (LAG-3, Ki67, Tim-3, ICOS expression on CD8+ T cells). This parameter change enables more accurate prediction of treatment response and better patient selection.
3Measurement precision
If tumor-based biomarkers like PD-L1 expression are used for patient selection, then some predictive value is obtained, but validation is inconsistent across studies and clinical utility is limited
Solution Approach 1:
The patent uses peripheral blood immune markers as intermediary indicators that reflect the patient's immune system readiness and capacity to respond to therapy. Rather than directly measuring tumor characteristics (PD-L1 expression), the patent measures the functional state of immune cells in circulation, providing a more reliable and consistent predictive biomarker.
Solution Approach 2:
The patent creates a surrogate biomarker system using peripheral blood samples that copies the predictive information traditionally obtained from tumor tissue analysis. By measuring immune marker expression in blood, the patent replicates the patient selection capability of tumor-based markers while avoiding the limitations of tissue availability and heterogeneity.
Data Source
AI summary
Provided are methods of assigning a LAG+, LAG−, or PRO immunotype to a cancer patient based on the frequencies of LAG-3+CD8+T-cells, Ki67+CD8+T-cells, Tim-3+CD8+T-cells, and ICOS+CD8+T-cells in a peripheral blood sample from the patient, and selecting an anti-cancer therapy, for example, an immune checkpoint blockade (ICB) therapy, based on the patient's immunotype.